Quantcast

Latest Cystic Fibrosis Foundation Therapeutics Inc. Stories

2009-09-10 07:00:00

SOUTH PLAINFIELD, N.J., Sept. 10 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the initiation of a Phase 3 trial of ataluren (formerly PTC124(R)), an investigational protein restoration therapy in patients with nonsense mutation cystic fibrosis (nmCF). Patients with CF lack adequate levels of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, a chloride channel necessary for normal function of the lung, pancreas, liver, and other organs. In nmCF, an...

2008-10-24 09:00:07

SOUTH PLAINFIELD, N.J. and ORLANDO, Fla., Oct. 24 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced that results from a randomized Phase 2a European study demonstrated that treatment with the investigational drug PTC124 caused statistically significant improvements in the chloride channel function of children with cystic fibrosis (CF) caused by a particular genetic mutation, called a nonsense mutation. Results from the study were presented today by Isabelle SermetGaudelus, M.D.,...

2008-10-21 06:00:24

EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, today announced that Martin Mense, Ph.D., principal scientist and head of Cystic Fibrosis biology at EPIX, is scheduled to present at the 22nd Annual North American Cystic Fibrosis Conference on Friday, October 24, 2008. Dr. Mense will participate in a symposium entitled...

2008-10-20 09:00:42

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from a preliminary analysis of data from Part 2 of the Phase 2a clinical trial of the investigational oral drug VX-770 in cystic fibrosis (CF) patients who carry the G551D CFTR mutation. VX-770, an investigational CFTR potentiator, was well-tolerated when dosed orally as 150 mg or 250 mg twice daily for 28 days. In this analysis, no patients discontinued treatment and no serious adverse events were reported....

2008-09-16 06:00:28

EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, today announced that it has achieved another milestone in its collaboration with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit affiliate of the Cystic Fibrosis Foundation. As a result, EPIX will receive $500,000 from CFFT, bringing the total amount of...

2008-07-16 09:01:20

SOUTH PLAINFIELD, N.J. and BETHESDA, Md., July 16 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) and Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit affiliate of the Cystic Fibrosis Foundation, today announced the expansion of an existing collaboration to support development of PTC124, the PTC's new investigational oral drug for the treatment of cystic fibrosis (CF) caused by nonsense mutations. PTC will receive up to $25 million from CFFT in support of key Phase 2b...

2008-07-08 09:01:11

FoldRx Pharmaceuticals, Inc. (FoldRx) today announced that it has discovered a series of novel drug prototypes that have shown potential in vitro to correct the protein-folding defect associated with cystic fibrosis (CF). The discovery, made through a research collaboration announced last year with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit affiliate of the Cystic Fibrosis Foundation, may pave the way to novel drugs capable of repairing the protein misfolding...


Word of the Day
tesla
  • The unit of magnetic flux density in the International System of Units, equal to the magnitude of the magnetic field vector necessary to produce a force of one newton on a charge of one coulomb moving perpendicular to the direction of the magnetic field vector with a velocity of one meter per second. It is equivalent to one weber per square meter.
This word is named for Nikola Tesla, the inventor, engineer, and futurist.